Suppr超能文献

尿胶原交联排泄:在骨Paget病中,它作为骨吸收指标是否比羟脯氨酸更好?

Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?

作者信息

Hamdy N A, Papapoulos S E, Colwell A, Eastell R, Russell R G

机构信息

Department of Endocrinology and Metabolic Diseases, University Hospital Leiden, The Netherlands.

出版信息

Bone Miner. 1993 Jul;22(1):1-8. doi: 10.1016/s0169-6009(08)80076-1.

Abstract

The 24 h urinary excretion of the collagen degradation products pyridinoline (Pyr) and deoxypyridinoline (Dpyr) have been proposed as specific and quantitative indices of bone resorption. We compared the value of the urinary excretion of Pyr and Dpyr to that of hydroxyproline (OHP) in 11 patients with Paget's disease of bone before and during treatment with inhibitors of bone resorption, during admission to a metabolic ward and maintenance on a gelatin-free diet. Pyr and Dpyr excretion rates were significantly correlated with those of OHP (r = 0.81 and 0.77, respectively, P < 0.001; n = 106). The rate and degree of suppression of bone resorption were monitored in 6 of the patients similarly treated with intravenous dimethyl-APD at a dose of 4 mg/day for 10 days, by daily measurements of the 24 h urinary excretion of Pyr, Dpyr and OHP. Treatment with dimethyl-APD resulted in a decrease in the three indices of bone resorption. The percentage change from baseline values was similar for the three indices, although changes in Dpyr appeared to follow more closely those of OHP. Our findings suggest that Pyr and Dpyr are useful and specific indices of bone resorption in Paget's disease of bone. They appear to confer no advantage, however, over the traditional determination of the urinary excretion of OHP, in the monitoring of response to treatment of such patients with inhibitors of bone resorption. Further studies are required to establish the value of these new biochemical indices of bone resorption, possibly in more subtle disorders of bone metabolism such as osteoporosis.

摘要

胶原降解产物吡啶啉(Pyr)和脱氧吡啶啉(Dpyr)的24小时尿排泄量已被提议作为骨吸收的特异性定量指标。我们比较了11例骨Paget病患者在代谢病房住院期间及维持无明胶饮食时,使用骨吸收抑制剂治疗前后Pyr和Dpyr的尿排泄量与羟脯氨酸(OHP)的尿排泄量。Pyr和Dpyr排泄率与OHP排泄率显著相关(r分别为0.81和0.77,P<0.001;n=106)。对6例以4mg/天的剂量静脉注射二甲基-APD持续10天进行类似治疗的患者,通过每日测量24小时尿中Pyr、Dpyr和OHP的排泄量来监测骨吸收的抑制率和抑制程度。二甲基-APD治疗导致骨吸收的三个指标均下降。尽管Dpyr的变化似乎更紧密地跟随OHP的变化,但这三个指标相对于基线值的百分比变化相似。我们的研究结果表明,Pyr和Dpyr是骨Paget病中骨吸收的有用且特异的指标。然而,在监测此类骨吸收抑制剂治疗患者的反应时,它们似乎并不比传统的尿OHP排泄量测定更具优势。需要进一步研究来确定这些新的骨吸收生化指标的价值,可能在诸如骨质疏松症等更细微的骨代谢紊乱中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验